Novel targets for the treatment of endometriosis

Bibliography

• HALME J, HAMMOND MG, HULKA JF et al.: Retrograde menstruation in healthy women and in patients with endometriosis. Obstet. Cynecol. (1984) 64:151–154.
   Google Scholar
• LIU DT, HITCHCOCK A: Endometriosis: its association with retrograde menstruation, dysmenorrhea, and tubal pathology. Br. j Obstet. Cynaecol. (1986) 93:859–886.
   PubMedGoogle Scholar
• ORAL E, OLIVE DL, ARICI A: The peritoneal environmental in endometriosis. Hum. Reprod. Update (1997) 2:385–398.
   Web of Science ®Google Scholar
• •A thorough review of the cytokines, such as TNF-a, associated with endometriosis.
   Google Scholar
• IWABE T, HARADA T, TSUDO T et al: Tumor necrosis factor-a promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. I Clin. Endocrinol. Metab. (2000) 85:824–829.
   PubMed Web of Science ®Google Scholar
• SILLEM M, PRIFTI S, MONGA B et al: Integrin-mediated adhesion of uterine endometrial cells from endometriosis patients to extracellular matrix proteins is enhanced by tumor necrosis factor alpha (TNFa) and interleukin-1 (IL-1). EIJI: I Obstet. Cynecol. Reprod. Biol. (1999) 87:123–127.
   Google Scholar
• •In vitro evidence that TNF-a enhances endometrial cell adhesion.
   Google Scholar
• WITZ CA, MONOTOYA-RODRIQUEZ IA, SCHENKEN RS: Whole explants of peritoneum and endometrium: a novel model of the early endometriosis lesion. Feral. Steril. (1999) 71:56–60.
   PubMed Web of Science ®Google Scholar
• WITZ CA, TAKAHASHI A, MONTOYA-RODRIGUEZ IA et al.: Expression of the a231 and a331 integrins at the surface of mesothelial cells: a potential attachment site of endometrial cells. Steril. (2000) 74:579–584.
   PubMed Web of Science ®Google Scholar
• WITZ CA, THOMAS MR, MONTOYA-RODRIGUEZ IA et al.: Short-term culture of peritoneum explants confirms attachment of endometrium to intact peritoneal mesothelium. Feral. Steril. (2001) 75:385–390.
   PubMed Web of Science ®Google Scholar
• GAETJE R, KOTZIAN S, HERRMANN G et al: Invasiveness of endometriotic cells M vitro. Lancet (1995) 346:1463–1464.
   PubMed Web of Science ®Google Scholar
• CORNILLIE FJ, OOSTERLYNCK D, LAUWERYNS JM et al: Deeply infiltrating pelvic endometriosis: histology and clinical significance. Steril. (1990) 53:978–983.
   PubMed Web of Science ®Google Scholar
• SPUIJBROEK MD, DUNSELMAN GA, MENHEERE PP et al.: Early endometriosis invades the extracellular matrix. Steril. (1992) 58:929–933.
   PubMed Web of Science ®Google Scholar
• ABBOTT JA, CLAYTON RD, CARRY R: The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2-5 year follow-up. Hum. Reprod. (2003) 9:1922–1927.
   Google Scholar
• OLIVE DL, PRITTS EA: The treatment of endometriosis. A review of the evidence. Ann. N Y Acad. Sci. (2002) 955:360–372.
   PubMed Web of Science ®Google Scholar
• •A review of current surgical and medical treatment regimens for endometriosis.
   Google Scholar
• MONTGOMERY-RICE V: Conventional medical therapies for endometriosis. Ann. N Y Acad. Sci. (2002) 955:343–352.
   PubMed Web of Science ®Google Scholar
• •A review of current medical treatment regimens for endometriosis.
   Google Scholar
• VALLE RF, SCIARRA JJ: Endometriosis: treatment strategies. Ann. N Y Acad. Sci. (2003) 997:229–239.
   PubMed Web of Science ®Google Scholar
• •A review of current medical treatment regimens for endometriosis.
   Google Scholar
• VERCELLINI P, CORTESI I, CROSIGNANI PG: Progestins for symptomatic endometriosis: a critical analysis of the evidence. Steril. (1997) 68:393–401.
   PubMed Web of Science ®Google Scholar
• FELBERBAUM RE, DIEDRICH K: Gonadotropin hormone-releasing antagonists: will they replace the agonists? Reprod. Biomed. Online (2003) 6:43–53.
   Google Scholar
• CLEMENS LE, SITTER PK, STITES DP: Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J. Immunol (1979) 122:1978–1985.
   PubMed Web of Science ®Google Scholar
• SCHUST DJ, ANDERSON DJ, HILL JA: Progesterone-induced immunosuppression is not mediated through the progesterone receptor. Hum. Reprod. (1996) 11:980–985.
   PubMed Web of Science ®Google Scholar
• OSTEEN KG, KELLER NR, FELTUS FA et al.: Paracrine regulation of matrix metalloproteinase expression in the normal endometrium. Cynecol Obstet. Invest. (1999) 48 (Suppl. 1):2–13.
   Google Scholar
• HILL JA, BARBIERI RL, ANDERSON DJ: Immunosuppressive effects of danazol M vitro. Fertil. m(1987) 48:414–418.
   PubMed Web of Science ®Google Scholar
• MORI H, NAKAGAWA M, ITOH N et al.: Danazol suppresses the production of interleukin-113 and tumor necrosis factor by human monocytes. Am..! Reprod. Immunol. (1990) 24:45–50.
   PubMed Web of Science ®Google Scholar
• OTA H, IGARASHI S, HAYAKAWA M et al.: Effect of danazol on the immunocompetent cells in the eutopic endometrium in patients with endometriosis: a multicenter cooperative study. Fertil. Steril. (1996) 65:545–551.
   PubMed Web of Science ®Google Scholar
• WU MY, CHAO KH, CHEN SU et al: The suppression of peritoneal cellular immunity in women with endometriosis could be restored after gonadotropin releasing hormone agonist treatment. Am. J. Reprod. I,nmunol. (1996) 35:510–516.
   PubMed Web of Science ®Google Scholar
• CHEN HF, JEUNG EB, STEPHENSON M et al.: Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH M vitro. I Clin. Endocrinol Metab. (1999) 84:743–750.
   PubMed Web of Science ®Google Scholar
• HARADA T, ENATSU A, MITSUNARI M et al.: Role of cytoldnes in progression of endometriosis. Cynecol Obstet. Invest. (1999) 47\(Suppl. 1):34–40.
   Google Scholar
• IMAI A, OHNO T, IIDA K et al: Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Cynecol Oncol (1994) 55:144–148.
   PubMed Web of Science ®Google Scholar
• IKEDA M, TAGA M, KUROGI K et al: Gene expression of gonadotropin-releasing hormone, but not its receptor in human endometrium and decidua. Ma Cell. Endocrinol (1997) 135:165–168.
   PubMed Web of Science ®Google Scholar
• BORRONI R, DI BLASIO AM, GAFFURI B et al.: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. MM. Cell. Endocrinol (2000) 159:37–43.
   PubMed Web of Science ®Google Scholar
• ADASHI EY: Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum. Reprod. Update (1994) 7:1380–1397.
   Google Scholar
• KIESEL L, SCHWEPPE KW, SILLEM M et al.: Should add-back therapy for endometriosis be deferred for optimal results? Br. Obstet. Cynaecol. (1996) 103\(Suppl. 14):15–17.
   Google Scholar
• SURREY ES: Add-back therapy and GnRH agonist in the treatment of patients with endometriosis: can a consensus be reached? Add-back consensus Working Group. Feral. Steril. (1999) 71:420–424.
   PubMed Web of Science ®Google Scholar
• WATANABE Y, NAKAMURA G, MATSUGUCHI H et al.: Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil. Steril. (1992) 58:66–71.
   PubMed Web of Science ®Google Scholar
• WHEELER JM, KNITTLE JD, MILLER JD: Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. Am. J. Obstet. Cynecol (1993) 169:26–33.
   PubMed Web of Science ®Google Scholar
• WARNOCK JK, BUNDREN JC, MORRIS DW: Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress. Anxiety (1998) 7:171–177.
   PubMedGoogle Scholar
• RACHMAN M, GARFIELD DA, RACHMAN I et al.: Lupron-induced mania. Biol. Psychiatry (1999) 45:243–244.
   PubMed Web of Science ®Google Scholar
• KUPKER W, FELBERBAUM RE, KRAPP M et al.: Use of GnRH antagonists in the treatment of endometriosis. Reprod. Biomed. Online (2002) 5:12–16.
   PubMedGoogle Scholar
• MURPHY AA, ZHOU MH, MALKAPURAM S et al: RU486-induced growth inhibition of human endometrial cells. Fertil. Steril. (2000) 74:1014–1019.
   PubMed Web of Science ®Google Scholar
• KETTEL LM, MURPHY AA, MORALES AJ et al.: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril (1996) 65:23–28.
   PubMed Web of Science ®Google Scholar
• KETTEL LM, MURPHY AA, MORALES AJ et al.: Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486). Am. J. Obstet. Cynecol (1998) 178:1151–1156.
   PubMed Web of Science ®Google Scholar
• STOECKEMANN K, HEGELE-HARTUNG C, CHWALISZ K: Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats. Hum. Reprod. (1995) 10:3264–3271.
   PubMed Web of Science ®Google Scholar
• FUHRMANN U, HESS-STUMMP H, CLEVE A et al.: Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J. Med. Chem. (2000) 43:5010–5016.
   PubMed Web of Science ®Google Scholar
• SLAYDEN OD, CHWALISZ K, BRENNER RIVI: Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum. Reprod. (2001) 8:1562–1574.
   Google Scholar
• NOBLE LS, SIMPSON ER, JOHNS A et al.: Aromatase expression in endometriosis. j Clin. Endocrinol Metab. (1996) 81:174–179.
   PubMed Web of Science ®Google Scholar
• BULUN SE, YANG S, FANG Z et al.: Estrogen production and metabolism in endometriosis. Ann. N Y Acad. Sci. (2002) 955:75–85.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA K, ZEITOUN K, GUNBY RT et al.: Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fend] Stern. (1998) 69:709–713.
   PubMed Web of Science ®Google Scholar
• AILAWADI RK, JOBANPUTRA S, KATARIA M et al.: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fern]. Stern. (2004) 81:290–296.
   PubMed Web of Science ®Google Scholar
• YANO S, IKEGAMI Y, NAKAO K: Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittelforschung (1996) 46:192–195.
   PubMed Web of Science ®Google Scholar
• KUDOH M, SUSAKI Y, IDEYAMA Y et al.: Inhibitory effects of a novel aromatase inhibitor, YM511, in rats with experimental endometriosis.j Steroid Biochein. MM. Biol. (1997) 63:1–3.
   Google Scholar
• GOTTSCHALK C, MALBERG K, ARNDT M et al.: Matrix metalloproteinases and TACE play a role in the pathogenesis of endometriosis. Adv. Exp. Med. Biol. (2000) 477:483–486.
   PubMed Web of Science ®Google Scholar
• KOKORINE I, NISOLLE M, DONNEZ J et al.: Expression of interstitial collagenase (matrix metalloproteinase-1) is related to the activity of human endometriotic lesions. Fern] Stern. (1997) 68:246–251.
   PubMed Web of Science ®Google Scholar
• MIZUMOTO H, SAITO T, ASHIHARA K et al.: Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. Life Sci. (2002) 71:259–273.
   PubMed Web of Science ®Google Scholar
• VVENZL RJ, HEINZL H: Localization of matrix metalloproteinase-2 in uterine endometrium and ectopic implants. Gynecol Obstet. Invest. (1998) 45:253–257.
   PubMed Web of Science ®Google Scholar
• CHUNG HW, LEE JY, MOON HS et al.: Matrix metalloproteinase-2, membranous Type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fern] Stern. (2002) 78:787–795.
   PubMed Web of Science ®Google Scholar
• SAITO T, MIZUMOTO H, KUROKI K et al.: Expression of MMP-3 and TIMP-1 in the endometriosis and the influence of danazol. Nippon Sanka Fujinka Gakkai Zasshi (1995) 47:495–496.
   PubMedGoogle Scholar
• CHUNG HW, WEN Y, CHUN SH et al: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. Fern] Steil]. (2001) 75:152–159.
   PubMed Web of Science ®Google Scholar
• GILABERT-ESTELLES J, ESTELLES A, GILABERT J et al.: Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum. Reprod. (2003) 18:1516–1522.
   PubMed Web of Science ®Google Scholar
• BRUNER KL, MATRISIAN LM, RODGERS WH et al: Suppression of matrix metalloproteinasesinhibits establishment of ectopic lesionsby human endometrium in nude mice.Clin. Invest. (1997) 99:2851–2857.
   Google Scholar
• ••In vivo study demonstrating that MMPsare needed for the establishment of endometriosis in a mouse model.
   Google Scholar
• BRUNER KL, EISENBERG E, GORSTEIN F et al.: Progesterone and transforming growth factor-I3 coordinately regulate suppression of endometrial matrix metalloproteinases in a model of experimental endometriosis. Steroids (1999) 64:648–653.
   PubMed Web of Science ®Google Scholar
• BRUNER-TRAN KL, VVEBSTER-CLAIR D, OSTEEN KG: Experimental endometriosis: the nude mouse as a xenograft host. Ann. N Y Acad. Sci. (2002) 955:328–339.
   PubMed Web of Science ®Google Scholar
• ••In vivo study demonstrating that MMPsare needed for the establishment of endometriosis in a mouse model.
   Google Scholar
• ORAL E, ARICI A: Pathogenesis of endometriosis. Obstet. Gynecol Clin. North Am. (1997) 24:219–233.
   PubMed Web of Science ®Google Scholar
• SIDELL N, HAN SW, PARTHASARATHY S: Regulation and modulation of abnormal immune responses in endometriosis. Ann. N Y Acad. Sci. (2002) 955:159–173.
   PubMed Web of Science ®Google Scholar
• GAZVANI R, TEMPLETON A: Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction (2002) 123:217–226.
   PubMed Web of Science ®Google Scholar
• TABIBZADEH S: The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Ma Hum. Reprod. (1996) 2:77–92.
   PubMed Web of Science ®Google Scholar
• SILLEM M, PRIFTI S, KOCH A et al: Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis. Ear: j Obstet. Gynecol Reprod. Biol. (2001) 95:167–174.
   PubMed Web of Science ®Google Scholar
• D'ANTONIO M, MARTELLI F, PEANO S et al.: Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally induced endometriosis in rats. J. Reprod. Immunol (2000) 48:81–98.
   Google Scholar
• ••In vivo study demonstrating thatblockage of TNF-a inhibits the ability of endometrosis growth in a rat model.
   Google Scholar
• D'HOOGHE TM, NUGENT N, CUNEO S et al: Recombinant human TNF binding protein (r-hTBP-1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Fern]. Stern. (2001) 76\(Suppl. 3):Sl.
   Google Scholar
• ••In vivo study demonstrating thatblockage of TNF-a inhibits the ability of endometrosis growth in a baboon model of endometriosis.
   Google Scholar
• BARRIER BE BATES GW, LELAND MW et al: Efficacy of anti-tumor necrosis factor therapy in treatment of spontaneous endometriosis in baboons. Fern]. Stern. 81 (Suppl. 1):775–779.
   Google Scholar
• ••In vivo study demonstratingthat etanercept reduces the severity of endometriosis in baboons with spontaneous disease.
   Google Scholar
• VIHINEN P, KAHARI VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer (2002) 99:157–166.
   PubMed Web of Science ®Google Scholar
• NELSON AR, FINGLETON B, ROTHERBERG ML et al.: Matrix metalloproteinases: biological activity and clinical applications. Clin. Oncol (2000) 18:1135–1149.
   Web of Science ®Google Scholar
• BURBRIDGE ME COGE F, GALIZZI JP et al.: The role of matrix metalloproteinases during M vitro vessel formation. Angiogenesis (2002) 5:215–226.
   Google Scholar
• UNEMORI EN, FERRARA N, BAUER EA, AMENTO EP: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. Cell. Physic] (1992) 153:557–562.
   PubMed Web of Science ®Google Scholar
• ETOH T, INOUE H, TANAKA S et al.:Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. (2001) 61:2145-2153. Expert Op/n. Ther. Targets (2004) 8(5)
   Google Scholar
• HIRATSUKA S, MARU Y, OKADA A et al.: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. (2001) 61:1207–1213.
   PubMed Web of Science ®Google Scholar
• BARCZ E, ROZEWSKA ES, KAMINSKI P et al.: Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int. j Gynaecol Obstet. (2002) 79:229–235.
   PubMed Web of Science ®Google Scholar
• MAHNKE JL, DAWOOD MY, HUANG JC: Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Ferti/. Stern. (2000) 73:166–170.
   PubMed Web of Science ®Google Scholar
• MCLAREN J, PRENTICE A, CHARNOCK-JONES DS, SMITH SK: Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum. Reprod. (1996) 11:220–223.
   PubMed Web of Science ®Google Scholar
• HULL ML, CHARNOCK-JONES DS, CHAN CL et al.: Antiangiogenic agents are effective inhibitors of endometriosis. Endocrinol Metab. (2003) 88:2889–2899.
   Google Scholar
• ••In vivo study which demonstratesthat inhibitors of VEGF can prevent the development of endometriosis in a mouse model.
   Google Scholar
• STEINLEITNER A, LAMBERT H, ROY S: Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Sterd. (1991) 55:26–31.
   PubMed Web of Science ®Google Scholar
• NOTHNICK WB, CURRY TE, VERNON MW: Immunomodulation of rat endometriotic implant growth and protein production. Am. J. Reprod. Immunol (1994) 31:151–162.
   PubMed Web of Science ®Google Scholar
• ••In vivo study demonstrating thatblockage of TNF-a using pentoxifylline inhibits the ability of endometrosis growth in a rat model, independently of steroid hormone levels.
   Google Scholar
• BALASCH J, CREUS M, FABREGUES F et al.: Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum. Reprod. (1997) 12:2046–2050.
   PubMed Web of Science ®Google Scholar
• WARD A, CLISSOLD SP: Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs (1987) 34:50–97.
   PubMed Web of Science ®Google Scholar
• ALKHARFY KM, KELLUM JA, MATZKE GR: Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock (2000) 13:346–360.
   Google Scholar
• MAKSYMOWYCH WP, AVINA-ZUBIETA A, LUONG MH et al: An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. Rheumatol (1995) 22:625–629.
   Web of Science ®Google Scholar
• REIMUND JM, BUMONT S, MULLER CD et al.: In vitro effects of pentoxifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut (1997) 40:475–480.
   PubMed Web of Science ®Google Scholar
• STRIETER RM, REMICK DG, WARD PA et al.: Cellular and molecular regulation of tumor necrosis factor-a by pentoxifylline. Biochem. Biophys. Res. Commun. (1988) 155:1230–1236.
   PubMed Web of Science ®Google Scholar
• SULLIVAN GW, CARPER HT, NOVICK WJ Jr et al.: Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect. Immun. (1988) 56:1722–1729.
   Google Scholar
• FOX RI, HERRMANN ML, FRANGOU CG et al: Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol a(1999) 93:198–208.
   PubMed Web of Science ®Google Scholar
• JARVIS B, FAULDS D: Etanercept: a review of its use in rheumatoid arthritis. Drugs (1999) 57:945–966.
   PubMed Web of Science ®Google Scholar
• MARKHAM A, LAMB HM: Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs (2000) 59:1341–1359.
   PubMed Web of Science ®Google Scholar
• NIKAS SN, DROSOS AA: Onercept. Serono. Carr. Opin. Investig. Drugs (2003) 4:1369–1376.
   PubMedGoogle Scholar
• BANG LM, KEATING GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs (2004) 18:121–139.
   PubMed Web of Science ®Google Scholar
• MEZYK R, BZOWAKA M, BERETA J: Structure and functions of tumor necrosis factor-a converting enzyme. Acta Biochim. Pol. (2003) 50:625–645.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, XU J, LEVIN J et al.: Identification and characterization of 4-[[4-(2-butynyloxy)phyenyl]sulfonyll -N-hydroxy-2,2-dimethyl-(3.5)-thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-a-converting enzyme/matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Pharmacol Exp. Ther. (2004) 309:348–355.
   Google Scholar
• CONWAY JG, ANDREWS RC, BEAUDET B et al.: Inhibition of tumor necrosis factor-a (TNF-a) production and arthritis in the rate by GW3333, a dual inhibitor of TNF-a-converting enzyme and matrix metalloproteinases. Pharmacol Exp. The]: (2001) 298:900–908.
   Google Scholar